Below you'll find a list of all posts that have been categorized as “Research News”
A pair of recent studies from the laboratory of Evangelos Kiskinis, PhD, associate professor in the Ken and Ruth Davee Department of Neurology’s Division of Neuromuscular Disease and of Neuroscience and a member of the Les Turner ALS Center at Northwestern Medicine, have uncovered novel …
As many as 2% of all ALS cases have been linked to mutations in the gene NEK1, making it one of the top-known causes of the disease. But it wasn’t known how the mutated gene disrupts the function of the …
En 2023, la Les Turner ALS Foundation financió casi $1 millón en subvenciones para la investigación de la ELA, así como para el apoyo a la clínica y al fondo de dotación del Les Turner ALS Center en Northwestern Medicine. …
The Lois Insolia ALS Clinic at the Les Turner ALS Center at Northwestern Medicine is now an active site for Regimen F of the HEALEY ALS Platform Trial. The focus of Regimen F is ABBV-CLS-7262, an investigational product being developed …
RE: FDA-2022-N-0691 Estimado Comité Asesor de la FDA: Le escribimos para expresar nuestro firme apoyo a la aprobación de tofersen bajo el Programa de Aprobación Acelerada de la FDA. Nuestra organización tiene una larga trayectoria en la investigación científica del …
Scientists from the Les Turner ALS Center at Northwestern Medicine have discovered two ways to preserve diseased upper motor neurons that would normally be destroyed in ALS, based on a study in mice. Upper motor neurons initiate movement, and they …
Your support of the Les Turner ALS Foundation is felt by people living with ALS, caregivers, families and loved ones everywhere. By making a donation or volunteering your time, you helped ensure they had the support they needed – and …
Researchers at Northwestern University and the Les Turner ALS Center at Northwestern Medicine have created the first highly mature neurons from human induced pluripotent stem cells (iPSCs), a feat that opens new opportunities for medical research and potential transplantation therapies …
On Monday October 17, 2022, the U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38 million in funding over the next four years to support clinical trials, natural history …
New results published this week provide further evidence that tofersen, a drug in development by Biogen, may be effective in slowing the progression of SOD1-ALS. As reported in the New England Journal of Medicine, the Phase 3 clinical trial (VALOR) …
